{"transactions":[{"id":1697956,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T17:00:07.000Z","date":"2023-12-29","kind":"other","planned":true,"acquired":true,"shares":406038,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Peter Harwin"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":406038,"source":{"system":"sec-edgar","filing":"0000950170-23-073904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023073904/ownership.xml","form_type":"4"}},{"id":1697955,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T17:00:07.000Z","date":"2023-12-29","kind":"other","planned":true,"acquired":true,"shares":406038,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":406038,"source":{"system":"sec-edgar","filing":"0000950170-23-073904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023073904/ownership.xml","form_type":"4"}},{"id":1697954,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T17:00:07.000Z","date":"2023-12-29","kind":"other","planned":true,"acquired":false,"shares":3435480,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P. (\"Fund I\"), Fairmount Healthcare Fund II L.P. (\"Fund II\") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-073904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023073904/ownership.xml","form_type":"4"}},{"id":1716308,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2023-12-11T17:41:01.000Z","date":"2023-12-07","kind":"grant","planned":false,"acquired":true,"shares":16667,"price":600,"value":10000200.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the \"Series B Preferred Stock\") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Preferred Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the \"Series B Preferred Stock\") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the \"Series B Preferred Stock\") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":16667,"derivative":{"underlying":"Common Stock","underlying_shares":666680},"source":{"system":"sec-edgar","filing":"0000950170-23-069455","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023069455/ownership.xml","form_type":"4"}},{"id":1728666,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-11-28T16:05:26.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":false,"shares":85887,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3435480},"source":{"system":"sec-edgar","filing":"0000950170-23-066399","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023066399/ownership.xml","form_type":"4"}},{"id":1728665,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T16:05:26.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":true,"shares":3435480,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":3435480,"source":{"system":"sec-edgar","filing":"0000950170-23-066399","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023066399/ownership.xml","form_type":"4"}}]}